drugset / Trial / NCT00829231

Hepatic Impairment Study

NCT00829231 ↗

Phase 1 Completed 45 enrolled Bayer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is to find out how the subject's body processes and reacts to the study drug, and to find out how long it remains in the subjects system after one dose. Subjects with varying degrees of liver function are being asked to participate in this study. Study results from subjects with normal liver function will be compared with study results from subjects with impaired liver function.

Timeline

Start
2009-01
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Sorafenib Small molecule — —

Indications